A leader from the trial solutions provider discusses how the COVID-19 pandemic has accelerated the already growing interest in remote patient monitoring.
The IQVIA and NORD study shows rare-disease treatments account for only 11% of new drug spending, but 80% of orphan products treat rare diseases alone.
The direct-to-patient service is designed to support trials and help to minimize trial length and costs, while boosting enrollment and participation rates.
The CRO will receive funding to fuel a five-year Research Project Award, with the goal to design and conduct research of potential PTSD treatment options.
The Verisense Pulse+ can measure heart rate, oxygen saturation, emotional responses, and activity and sleep levels of at-home clinical trial participants.
A leader from the genetic solutions firm explains how genetic testing and counseling can help trial teams form more beneficial connections with patients.
The partnership reportedly will center on optimizing integration for EHR data and remote-source data review to help accelerate clinical research results.
An executive from the rare disease technology solutions company discusses how forcing connections with patients can boost research into such conditions.
An executive from the clinical trial technology provider will share how direct data capture can save time, avoid errors and improve the patient experience.
The annual event, moved to the virtual realm thanks to COVID-19, offers content on remote monitoring, drug development technology and other key topics.
The collaboration will leverage patients’ biological and medical data to streamline patient identification and recruitment efforts in clinical research.
A senior clinical research associate from the CRO discusses how the pandemic has touched her workday, and how she is dealing with the myriad challenges.
The technology is designed to streamline and simplify integration, data collection and analysis, and digital biomarker discovery with wearable sensors.
The on-pack technology enables consumers, retailers and others to harness mobile devices in order to verify the authenticity of pharmaceutical products.
The two companies will work to advance precision cancer medicine by harnessing genomics data in trial design, recruitment, site selection and other areas
A leader from the clinical data solutions firm explains how the challenges created by the pandemic have helped fuel creativity and innovation in studies.
In the drive to advance personalized medicine, researchers are increasingly turning to radiomics to assist in the discovery of new types of biomarkers.
A study by two trial technology firms reportedly indicates that decentralized trials are outperforming on-site in recruitment, retention and other aspects.
The American Heart Association’s Heart of Communicating Science modules are designed to help experts break complex talk into easy-to-understand language.
According to a company leader, electronic clinical outcome assessment solutions should take ease of use for patients, sponsors and others into account.
William Gholston, with the Tampa Bay Buccaneers football team, is donating to the Moffitt Cancer Center to fund research into cancer treatment disparities.
The founder of Andaman7’s leukemia diagnosis, and his son’s experience with bone cancer, have helped inform the firm's tech and patient-centric approach.
Thanks to collaborations with Cerner, amassing of proprietary data and other achievements, the trial solutions firm has hit a significant access milestone.
The two companies are integrating their technologies in a move designed to help hasten trial launches, and get promising new treatments to market faster.
Bioclinica’s Image Redact AI tool enables trials to edit sensitive information from videos, photos and PDFs to ensure compliance and safeguard patient data
The company’s medical imaging technology and other eClinical solutions reportedly played a part in half of the treatments to receive the FDA designation.
With fewer than 3% of analyzed genomes currently coming from Africans, the companies are looking to increase access to and understanding of patient data.
Conducted by SubjectWell, the survey of patients with Type 2 diabetes reveals how ethnicity and other factors play a part in trial participation tendencies.
Two leaders from the clinical technology solutions company discuss how digital tools like eCOAs have been invaluable in facing pandemic-related challenges.
The trials, funded by the American Heart Association, will harness the company’s Verisense wearable sensor platform to examine brain-heart health links.
Formerly Parexel Informatics, the renamed clinical research technology company has broken off and will operate as an independent company going forward.
The pharma giant has invested in the clinical trial exploring the viability of Vedanta Biosciences’ VE202 inflammatory bowel disease treatment candidate.
A leader from Oracle Health Sciences examines the dynamic, challenging year and highlights creativity and ingenuity displayed by research professionals.
A representative from the global CRO outlines how forces like COVID-19, decentralized studies, globalization and others are driving change in the industry.
